Cargando…

The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice

BACKGROUND: Fingolimod (Gilenya®) is an oral medication for patients with highly active relapsing-remitting Multiple Sclerosis (RRMS). Clinical trials and post-marketing experience on more than 114,000 patients have established a detailed safety profile. Total patient exposure now exceeds 195,000 pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ziemssen, Tjalf, Kern, Raimar, Cornelissen, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472406/ https://www.ncbi.nlm.nih.gov/pubmed/26084334 http://dx.doi.org/10.1186/s12883-015-0342-0

Ejemplares similares

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL
por: Alsop, Jonathan, et al.
Publicado: (2017)

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System
por: Kern, Raimar, et al.
Publicado: (2016)

Data Collection in Multiple Sclerosis: The MSDS Approach
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Use and Acceptance of Electronic Communication by Patients With Multiple Sclerosis: A Multicenter Questionnaire Study
por: Haase, Rocco, et al.
Publicado: (2012)

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study
por: Ness, Nils-Henning, et al.
Publicado: (2020)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol
por: Dirks, Petra, et al.
Publicado: (2020)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol
por: Vormfelde, Stefan Viktor, et al.
Publicado: (2016)

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis
por: Inojosa, Hernan, et al.
Publicado: (2020)

On the Reliability of Examining Dual-Tasking Abilities Using a Novel E-Health Device—A Proof of Concept Study in Multiple Sclerosis
por: Böttrich, Niels, et al.
Publicado: (2020)

The PANGAEA mineralogical database
por: Drozdovskiy, Igor, et al.
Publicado: (2020)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
por: Butzkueven, Helmut, et al.
Publicado: (2022)

A Digital Patient Portal for Patients With Multiple Sclerosis
por: Voigt, Isabel, et al.
Publicado: (2020)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study
por: Totaro, Rocco, et al.
Publicado: (2015)

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
por: Klotz, Luisa, et al.
Publicado: (2015)

Fatigue and Sleep in Multiple Sclerosis Patients: A Comparison of Self-Report and Performance-Based Measures
por: Paucke, Madlen, et al.
Publicado: (2018)

PANGAEA - Data Publisher for Earth & Environmental Science
por: Felden, Janine, et al.
Publicado: (2023)

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration
por: Sehr, Tony, et al.
Publicado: (2020)

Patients’ preferences for involvement in the decision-making process for treating diabetic retinopathy
por: Marahrens, Lydia, et al.
Publicado: (2017)

Design of a prospective, multicenter, global, cohort study of electromagnetic navigation bronchoscopy
por: Folch, Erik E., et al.
Publicado: (2016)

Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
por: Akgün, Katja, et al.
Publicado: (2019)

The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design
por: Oh, Jiwon, et al.
Publicado: (2021)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease
por: Thomas, Katja, et al.
Publicado: (2014)

A prospective observational cohort study of posterior tibial nerve stimulation in patients with multiple sclerosis: design and methods
por: Lane, Giulia I., et al.
Publicado: (2020)

Strengthening the occupational and social participation of multiple sclerosis patients - design of a multicenter, parallel-group randomized controlled trial (MSnetWork-study)
por: Meyer-Moock, Sandra, et al.
Publicado: (2022)

Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2008)

Pressure ulcer incidence in Dutch and German nursing homes: design of a prospective multicenter cohort study
por: Meesterberends, Esther, et al.
Publicado: (2011)

Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t5u8h3asegqh7hbcg5drocjlpg